{"id":"peg-filgrastim","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Bone pain"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Injection site reaction"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Peg-filgrastim works by binding to and activating the granulocyte colony-stimulating factor receptor (G-CSFR), which triggers the release of neutrophils from the bone marrow into the bloodstream. This helps to increase the number of neutrophils in the body, reducing the risk of infection in patients undergoing chemotherapy or other treatments that suppress the immune system.","oneSentence":"Peg-filgrastim stimulates the production of white blood cells, specifically neutrophils, to help the body fight infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:06.183Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy"},{"name":"Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy after autologous bone marrow transplantation"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT00066443","phase":"PHASE1, PHASE2","title":"Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":93},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT06528691","phase":"PHASE2","title":"Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-04","conditions":"High Grade Glioma, CNS Tumor","enrollment":52},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":"Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma","enrollment":38},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT03214562","phase":"PHASE1, PHASE2","title":"Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-26","conditions":"High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT03609216","phase":"PHASE2","title":"Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2018-12-10","conditions":"Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma","enrollment":271},{"nctId":"NCT06048484","phase":"PHASE2","title":"Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma","status":"RECRUITING","sponsor":"Gulam Manji","startDate":"2024-05-10","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":60},{"nctId":"NCT04684368","phase":"PHASE2","title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-07-13","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma","enrollment":160},{"nctId":"NCT03007147","phase":"PHASE3","title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2017-08-08","conditions":"Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia","enrollment":475},{"nctId":"NCT07192770","phase":"","title":"G-CSF-Induced Bone Pain and Supportive Care Approaches","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2025-09-27","conditions":"Solid Tumors, Chemotherapy-induced Neutropenia","enrollment":225},{"nctId":"NCT06709495","phase":"PHASE1, PHASE2","title":"Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas","status":"RECRUITING","sponsor":"David S Shulman, MD","startDate":"2025-01-27","conditions":"Sarcoma, Sarcoma, Ewing, Desmoplastic Small Round Cell Tumor","enrollment":63},{"nctId":"NCT05296317","phase":"NA","title":"Evaluation and Modeling of the Effect of G-CSF on the Evolution of Polynuclear Neutrophils During Dense Dose Epirubicin-Cyclophosphamide Regeneration","status":"COMPLETED","sponsor":"Centre Georges Francois Leclerc","startDate":"2022-09-02","conditions":"Localized Breast Cancer","enrollment":97},{"nctId":"NCT07419295","phase":"PHASE3","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-17","conditions":"Bladder Cancer","enrollment":590},{"nctId":"NCT07416955","phase":"PHASE1","title":"Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults","status":"COMPLETED","sponsor":"Kashiv BioSciences, LLC","startDate":"2025-04-05","conditions":"Healthy Volunteer","enrollment":180},{"nctId":"NCT04685616","phase":"PHASE3","title":"Brentuximab Vedotin in Early Stage Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University College, London","startDate":"2022-04-14","conditions":"Hodgkin Lymphoma","enrollment":1042},{"nctId":"NCT03147612","phase":"PHASE2","title":"Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-02-08","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1","enrollment":22},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia","enrollment":42},{"nctId":"NCT03301350","phase":"PHASE2","title":"Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-11-07","conditions":"Breast Cancer, Triple Negative Breast Cancer","enrollment":29},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT05753618","phase":"PHASE4","title":"Evaluating Omission of Granulocyte Colony-stimulating Factors in Breast Cancer Patients Receiving Paclitaxel Portion of Dose-dense Adriamycin-cyclophosphamide and Paclitaxel Chemotherapy","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2023-04-17","conditions":"Early-stage Breast Cancer","enrollment":242},{"nctId":"NCT04872543","phase":"PHASE2","title":"A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-04-29","conditions":"Malignant Peripheral Nerve Sheath Tumors (MPNST)","enrollment":25},{"nctId":"NCT07125183","phase":"PHASE2","title":"Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-12","conditions":"Sarcoma","enrollment":20},{"nctId":"NCT06594939","phase":"PHASE2","title":"Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2026-03","conditions":"Diffuse Large B Cell Lymphoma (DLBCL)","enrollment":31},{"nctId":"NCT04323956","phase":"PHASE1","title":"Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-06-15","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma","enrollment":50},{"nctId":"NCT03943901","phase":"PHASE2","title":"Split-Dose R-CHOP for Older Adults With DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2021-02-17","conditions":"Diffuse Large B Cell Lymphoma, DLBCL, Cancer","enrollment":27},{"nctId":"NCT05634369","phase":"PHASE1, PHASE2","title":"A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-11-14","conditions":"Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed","enrollment":50},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT07059611","phase":"PHASE2","title":"Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2026-04-01","conditions":"Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":34},{"nctId":"NCT05211336","phase":"PHASE1","title":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-04-19","conditions":"Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS), Aggressive B-cell Lymphoma With Secondary Involvement of the CNS","enrollment":14},{"nctId":"NCT04174742","phase":"","title":"Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2019-12-17","conditions":"Breast, Breast Cancer","enrollment":102},{"nctId":"NCT06220032","phase":"PHASE3","title":"Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma","status":"RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2024-08-15","conditions":"DLBCL - Diffuse Large B Cell Lymphoma","enrollment":324},{"nctId":"NCT06414889","phase":"PHASE1","title":"Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-05-20","conditions":"RUNX1 Familial Platelet Disorder","enrollment":4},{"nctId":"NCT05130827","phase":"PHASE2","title":"Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-12-21","conditions":"Multiple Myeloma","enrollment":17},{"nctId":"NCT06690775","phase":"PHASE2","title":"CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","status":"RECRUITING","sponsor":"TORL Biotherapeutics, LLC","startDate":"2024-11-20","conditions":"Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer","enrollment":230},{"nctId":"NCT01850888","phase":"NA","title":"MIBG for Refractory Neuroblastoma and Pheochromocytoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2013-12","conditions":"Relapsed Neuroblastoma, Metastatic Pheochromocytoma","enrollment":15},{"nctId":"NCT01871766","phase":"PHASE2","title":"Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-12-04","conditions":"Rhabdomyosarcoma","enrollment":115},{"nctId":"NCT07278856","phase":"PHASE1","title":"Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-04-27","conditions":"Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type","enrollment":20},{"nctId":"NCT01046825","phase":"PHASE2, PHASE3","title":"Mature B-Cell Lymphoma And Leukemia Study III","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2010-09-09","conditions":"Mature B-Cell Lymphoma","enrollment":128},{"nctId":"NCT03907488","phase":"PHASE3","title":"Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-29","conditions":"Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma","enrollment":994},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT01840566","phase":"PHASE1","title":"High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-04","conditions":"Non-Hodgkin's Lymphoma","enrollment":17},{"nctId":"NCT07188090","phase":"PHASE2","title":"Mozobil for Autologous Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-10-16","conditions":"Multiple Myeloma, Hodgkin Lymphoma, Non-hodgkin Lymphoma","enrollment":100},{"nctId":"NCT02810743","phase":"PHASE3","title":"Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-01-25","conditions":"Breast Cancer","enrollment":174},{"nctId":"NCT03571633","phase":"PHASE2","title":"Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Leon Berard","startDate":"2018-08-06","conditions":"HER2-positive Breast Cancer, Operable Breast Cancer","enrollment":90},{"nctId":"NCT06711523","phase":"PHASE3","title":"Study Evaluating PEG-G-CSF Injectionin Preventing Neutropenia After Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kexing Biopharm Co., Ltd.","startDate":"2025-01-09","conditions":"Neutropenia, Chemotherapy-Induced Febrile, Breast Neoplasm Female","enrollment":250},{"nctId":"NCT01933932","phase":"PHASE3","title":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2013-09-25","conditions":"Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV","enrollment":510},{"nctId":"NCT02369458","phase":"PHASE2","title":"Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2015-04-14","conditions":"Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck","enrollment":48},{"nctId":"NCT03036488","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-07","conditions":"Triple Negative Breast Neoplasms","enrollment":1174},{"nctId":"NCT02909036","phase":"PHASE1","title":"Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-09","conditions":"Multiple Myeloma, Amyloidosis","enrollment":46},{"nctId":"NCT01624805","phase":"PHASE2","title":"Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-25","conditions":"Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome","enrollment":140},{"nctId":"NCT05645718","phase":"PHASE2","title":"Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-07-14","conditions":"Leukemia","enrollment":27},{"nctId":"NCT05870748","phase":"PHASE2, PHASE3","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","status":"TERMINATED","sponsor":"Sutro Biopharma, Inc.","startDate":"2023-07-12","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":600},{"nctId":"NCT07184021","phase":"PHASE2","title":"Neoadjuvent Dose-dense Gemcitabine and Cisplatin In Muscle Invasive Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-09","conditions":"Urinary Bladder Cancer","enrollment":30},{"nctId":"NCT04383743","phase":"PHASE2","title":"Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-11-24","conditions":"Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma","enrollment":17},{"nctId":"NCT03107988","phase":"PHASE1","title":"NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2017-09-05","conditions":"Neuroblastoma","enrollment":65},{"nctId":"NCT03860844","phase":"PHASE2","title":"Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia","enrollment":67},{"nctId":"NCT00911183","phase":"PHASE2","title":"Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2008-12-02","conditions":"Lymphoma","enrollment":67},{"nctId":"NCT05573386","phase":"","title":"Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim","status":"COMPLETED","sponsor":"Andrews Research & Education Foundation","startDate":"2021-08-09","conditions":"Healthy","enrollment":15},{"nctId":"NCT06616987","phase":"PHASE2","title":"Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Yeon Hee Park","startDate":"2025-07-03","conditions":"Breast Cancer Metastatic","enrollment":40},{"nctId":"NCT03646123","phase":"PHASE2","title":"Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Seagen Inc.","startDate":"2019-01-28","conditions":"Hodgkin Lymphoma","enrollment":255},{"nctId":"NCT05011188","phase":"PHASE1, PHASE2","title":"FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rahul Aggarwal","startDate":"2022-01-19","conditions":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer","enrollment":44},{"nctId":"NCT00334815","phase":"PHASE2","title":"Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-06-15","conditions":"Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma","enrollment":29},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT05032183","phase":"PHASE1, PHASE2","title":"Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-17","conditions":"Recurrent Adult Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT00049595","phase":"PHASE3","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2002-08","conditions":"Lymphoma","enrollment":552},{"nctId":"NCT00070564","phase":"PHASE3","title":"S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2003-11","conditions":"Breast Cancer","enrollment":3294},{"nctId":"NCT03220022","phase":"PHASE1","title":"Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-03-16","conditions":"AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","enrollment":46},{"nctId":"NCT07064018","phase":"PHASE1, PHASE2","title":"Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2025-04-30","conditions":"Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer","enrollment":67},{"nctId":"NCT00812669","phase":"PHASE2","title":"CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2008-08-18","conditions":"Leukemia","enrollment":52},{"nctId":"NCT04506554","phase":"PHASE2","title":"A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2020-12-01","conditions":"Muscle-Invasive Bladder Carcinoma","enrollment":81},{"nctId":"NCT06698861","phase":"PHASE1","title":"A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2024-08-19","conditions":"PK in Healthy Volunteers","enrollment":30},{"nctId":"NCT02582697","phase":"PHASE3","title":"Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours","status":"RECRUITING","sponsor":"University of Sydney","startDate":"2014-02","conditions":"Germ Cell Tumor","enrollment":500},{"nctId":"NCT06958614","phase":"","title":"Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC","status":"COMPLETED","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2019-09-02","conditions":"Stage II-III Non-small Cell Lung Cancer, Concurrent Chemotherapy, Conditions Influencing Health Status","enrollment":213},{"nctId":"NCT01437488","phase":"PHASE2","title":"Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2012-02-16","conditions":"Urothelial Carcinoma","enrollment":14},{"nctId":"NCT06918587","phase":"PHASE1","title":"Open Label Randomized Comparative Crossover Pharmacokinetic and Immunogenicity Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kashiv BioSciences, LLC","startDate":"2024-09-05","conditions":"Febrile Neutropenia","enrollment":180},{"nctId":"NCT03844360","phase":"PHASE4","title":"Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease","status":"RECRUITING","sponsor":"Wei Zhao","startDate":"2016-01-31","conditions":"Hematological Neoplasms","enrollment":1500},{"nctId":"NCT04781959","phase":"PHASE4","title":"A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-06-09","conditions":"Early-stage Breast Cancer","enrollment":233},{"nctId":"NCT04023669","phase":"PHASE1","title":"Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2019-08-08","conditions":"Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory","enrollment":21},{"nctId":"NCT00670358","phase":"PHASE1, PHASE2","title":"Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-08-25","conditions":"Lymphoma","enrollment":138},{"nctId":"NCT05910164","phase":"","title":"Patient Preference Between a Prefilled Syringe or a Prefilled Pen Device for Administration of Pegfilgrastim","status":"COMPLETED","sponsor":"Institut Rafael","startDate":"2023-06-09","conditions":"Patient Preference, Febrile Neutropenia, Drug-Induced, Patient Satisfaction","enrollment":150},{"nctId":"NCT03649438","phase":"","title":"131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma","status":"NO_LONGER_AVAILABLE","sponsor":"University of Texas Southwestern Medical Center","startDate":"","conditions":"Relapsed Neuroblastoma, Metastatic Pheochromocytoma","enrollment":""},{"nctId":"NCT06094140","phase":"PHASE2","title":"NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2022-05-20","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT02938442","phase":"PHASE1, PHASE2","title":"Vaccination of Triple Negative Breast Cancer Patients","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2019-01-25","conditions":"Triple Negative Breast Cancer, Breast Neoplasms","enrollment":16},{"nctId":"NCT03885284","phase":"PHASE1","title":"Study of Proton Therapy in Adjuvant Pancreatic Cancer","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2019-07-15","conditions":"Resected Pancreatic Adenocarcinoma","enrollment":9},{"nctId":"NCT05841186","phase":"NA","title":"Correlation of Timing of Pegfilgrastim Administration and PIBP.","status":"RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2023-05-04","conditions":"Pegfilgrastim, Bone Pain, Chemotherapy","enrollment":156},{"nctId":"NCT03102606","phase":"PHASE3","title":"Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3","status":"COMPLETED","sponsor":"BeyondSpring Pharmaceuticals Inc.","startDate":"2018-05-29","conditions":"Chemotherapy-induced Neutropenia","enrollment":105},{"nctId":"NCT04873765","phase":"PHASE1","title":"Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers","status":"COMPLETED","sponsor":"Megalabs","startDate":"2022-03-18","conditions":"Neutropenia","enrollment":72},{"nctId":"NCT05194579","phase":"PHASE1","title":"Pharmacokinetic Comparability Study in Healthy Participants - PF-06881894 On-Body Injector Relative to Prefilled Syringe","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-02-10","conditions":"Healthy Volunteers","enrollment":141},{"nctId":"NCT06520176","phase":"PHASE3","title":"Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08","conditions":"Multiple Myeloma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT00557193","phase":"PHASE3","title":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2008-01-15","conditions":"Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia","enrollment":218},{"nctId":"NCT01782339","phase":"PHASE2","title":"A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2012-05-01","conditions":"Germ Cell Tumour","enrollment":45},{"nctId":"NCT02073097","phase":"PHASE1, PHASE2","title":"Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-01-28","conditions":"Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma","enrollment":48},{"nctId":"NCT05043649","phase":"PHASE1","title":"Camsirubicin + Pegfilgrastim to Determine MTD in ASTS","status":"TERMINATED","sponsor":"Monopar Therapeutics","startDate":"2021-09-22","conditions":"Advanced Soft-tissue Sarcoma","enrollment":14},{"nctId":"NCT04345900","phase":"PHASE2","title":"Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2","status":"COMPLETED","sponsor":"BeyondSpring Pharmaceuticals Inc.","startDate":"2017-04-05","conditions":"Chemotherapy-induced Neutropenia","enrollment":55},{"nctId":"NCT03433560","phase":"","title":"An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)","status":"COMPLETED","sponsor":"Kyowa Kirin Korea Co., Ltd.","startDate":"2018-01-18","conditions":"Breast Cancer Female, Breast Neoplasm Female","enrollment":1300}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"DEATH"},{"count":4,"reaction":"FEBRILE NEUTROPENIA"},{"count":3,"reaction":"NEUTROPENIA"},{"count":3,"reaction":"OROPHARYNGEAL PAIN"},{"count":3,"reaction":"URTICARIA"},{"count":2,"reaction":"DISEASE PROGRESSION"},{"count":2,"reaction":"DRUG HYPERSENSITIVITY"},{"count":2,"reaction":"ODYNOPHAGIA"},{"count":2,"reaction":"PYREXIA"},{"count":2,"reaction":"SEPSIS"}],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Neulastaᵀᴹ pfs inj. 6mg/0.6ml","pegylated filgrastim","PEG filgrastim","SD-01","Neulasta(R)"],"phase":"phase_3","status":"active","brandName":"Peg-filgrastim","genericName":"Peg-filgrastim","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Peg-filgrastim stimulates the production of white blood cells, specifically neutrophils, to help the body fight infection. Used for Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, Reducing the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy after autologous bone marrow transplantation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}